Monte Rosa Therapeutics (GLUE) Research & Development (2020 - 2026)
Monte Rosa Therapeutics (GLUE) recorded Research & Development of $47.96 million in Q2 2026, up 56.5% from $30.65 million a year earlier and up 8.8% from the prior quarter.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Research & Development (2020 - 2026) Analysis & Trends
On a TTM basis, Monte Rosa Therapeutics' Research & Development came in at $170.69 million as of Jun 30, 2026, up 32.0% year-over-year; for FY2025, it came in at $141.5 million, up 16.4% from FY2024.
- Annual Research & Development has increased for five straight years, with a five-year compound annual growth rate of 42.6% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $121.56 million in FY2024 (+9.2%), $111.27 million in FY2023 (+30.8%), $85.06 million in FY2022 (+48.8%) and $57.16 million in FY2021 (+138.1%).
- The Q2 2026 figure is the highest quarterly Research & Development in data going back to Q2 2020.
- On a year-over-year basis, Research & Development has increased for seven consecutive quarters, with growth averaging 25.4% over the last eight quarters.
- Peak year-over-year performance for Research & Development in the last five years was growth of 176.2% in Q3 2021, against a decline of 3.5% in Q2 2024 at the low end.
- Per Business Quant, the preceding three quarters came in at $44.07 million (Q1 2026), $41.98 million (Q4 2025) and $36.68 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Monte Rosa Therapeutics | 998.00 Mn | 409.81 Mn | - | 47.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47.96 Mn |
| Mar 31, 2026 | 44.07 Mn |
| Dec 31, 2025 | 41.98 Mn |
| Sep 30, 2025 | 36.68 Mn |
| Jun 30, 2025 | 30.65 Mn |
| Mar 31, 2025 | 32.19 Mn |
| Dec 31, 2024 | 38.87 Mn |
| Sep 30, 2024 | 27.62 Mn |
| Jun 30, 2024 | 28.06 Mn |
| Mar 31, 2024 | 27.03 Mn |
| Dec 31, 2023 | 27.14 Mn |
| Sep 30, 2023 | 28.31 Mn |
| Jun 30, 2023 | 29.08 Mn |
| Mar 31, 2023 | 26.76 Mn |
| Dec 31, 2022 | 24.87 Mn |
| Sep 30, 2022 | 21.34 Mn |
| Jun 30, 2022 | 20.94 Mn |
| Mar 31, 2022 | 17.92 Mn |
| Dec 31, 2021 | 18.13 Mn |
| Sep 30, 2021 | 15.12 Mn |
API Access
Monte Rosa Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=GLUE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "GLUE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=GLUE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();